Federal Register / Vol. 74, No. 119 / Tuesday, June 23, 2009 / Notices 29719 

Administration (DEA) to be registered as 

an importer of Phenylacetone (8501), a 

basic class of controlled substance listed 

in schedule II. 

The company plans to import the 

listed controlled substance to bulk 

manufacture amphetamine. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than July 23, 2009. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import the basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: June 15, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–14729 Filed 6–22–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such substances, provide manufacturers 

holding registrations for the bulk 

manufacture of the substance an 

opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on May 28, 

2009, Aptuit (Allendale) Inc., 75 

Commerce Drive, Allendale, New Jersey 

07401, made application by renewal to 

the Drug Enforcement Administration 

(DEA) for registration as an importer of 

the basic classes of controlled 

substances listed in schedule II. 

Drug Schedule 

Lisdexamfetamine (1205) ............... II 

Noroxymorphone (9668) ................ II 

The company plans to import the 

basic classes of controlled substances 

for clinical trials and research. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances may file comments or 

objections to the issuance of the 

proposed registration and may, at the 

same time, file a written request for a 

hearing on such application pursuant to 

21 CFR 1301.43 and in such form as 

prescribed by 21 CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than July 23, 2009. 

This procedure is to be conducted 

simultaneously with and independent 

of, the procedures described in 21 CFR 

1301.34(b),(c),(d),(e) and (f). As noted in 

a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import the basic classes 

of any controlled substances in schedule 

I or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: June 15, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–14724 Filed 6–22–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 27, 2009, 

Boehringer Ingelheim Chemicals, Inc., 

2820 N. Normandy Drive, Petersburg, 

Virginia 23805, made application by 

renewal to the Drug Enforcement 

Administration (DEA) as a bulk 

manufacturer of the basic classes of 

controlled substances listed in schedule 

II: 

Drug Schedule 

Amphetamine (1100) .................... II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

The company plans to manufacture 

the listed controlled substances in bulk 

for sale to its customers for formulation 

into finished pharmaceuticals. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than August 24, 2009. 

Dated: June 15, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–14707 Filed 6–22–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to Section 1301.33(a) of Title 

21 of the Code of Federal Regulations 

(CFR), this is notice that on May 22, 

2009, Noramco Inc., Division of OrthoMcNeil, Inc., 1440 Olympic Drive, 

Athens, GA 30601, made application by 

letter to the Drug Enforcement 

Administration (DEA) for registration as 

a bulk manufacturer of Tapentadol 

29720 Federal Register / Vol. 74, No. 119 / Tuesday, June 23, 2009 / Notices 

(9780), a basic class of controlled 

substance listed in schedule II. 

The company plans to bulk 

manufacture the above listed controlled 

substance for distribution to its 

customers. 

Any other such applicant and any 

person who is presently registered with 

DEA to manufacture such a substance 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, VA 22152; and must be 

filed no later than August 24, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–14705 Filed 6–22–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

DRUG ENFORCEMENT 

ADMINISTRATION 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to Section 1301.33(a) of Title 

21 of the Code of Federal Regulations 

(CFR), this is notice that on May 1, 

2009, Noramco Inc., Division of OrthoMcNeil, Inc., 1440 Olympic Drive, 

Athens, Georgia 30601, made 

application by letter to the Drug 

Enforcement Administration (DEA) for 

registration as a bulk manufacturer of 

Noroxymorphone (9668), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to bulk 

manufacture the above listed controlled 

substance for distribution to its 

customers. 

Any other such applicant and any 

person who is presently registered with 

DEA to manufacture such a substance 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, VA 22152; and must be 

filed no later than August 24, 2009. 

Dated: June 15, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–14704 Filed 6–22–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to Section 1301.33(a) of Title 

21 of the Code of Federal Regulations 

(CFR), this is notice that on May 22, 

2009, Noramco Inc., Division of OrthoMcNeil, Inc., 500 Swedes Landing Road, 

Wilmington, Delaware 19801, made 

application by letter to the Drug 

Enforcement Administration (DEA) for 

registration as a bulk manufacturer of 

Tapentadol (9780), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to bulk 

manufacture the above listed controlled 

substance for distribution to its 

customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such a substance, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, VA 22152; and must be 

filed no later than August 24, 2009. 

Dated: June 15, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–14695 Filed 6–22–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Office of the Secretary; ‘‘Promotion of 

Labor Rights and Employment in 

Pakistan’’ 

June 17, 2009. 

AGENCY: Bureau of International Labor 

Affairs, Department of Labor. 

Announcement Type: New. Notice of 

Availability of Funds and Solicitation 

for Cooperative Agreement 

Applications. The full announcement is 

posted on http://www.Grants.gov. 

Funding Opportunity Number: SGA– 

09–07. 

Key Dates: The closing date for receipt 

of applications is July 31, 2009 via 

Grants.gov. Applications may also be 

submitted by mail. 

Funding Opportunity Description 

The U.S. Department of Labor 

(USDOL), Bureau of International Labor 

Affairs (ILAB), announces the 

availability of funds in the amount of 

U.S. $1,600,000 to be awarded by 

Cooperative Agreement to a qualifying 

organization for the purpose of 

implementing a worker rights and 

employment demonstration project that 

assists unemployed Pakistanis with 

vocational and entrepreneurial training 

to obtain employment or pursue 

professions and acquire an 

understanding of their fundamental 

rights as workers. The project will take 

place in the Federally Administered 

Tribal Areas, the Northwest Frontier 

Province and Baluchistan. Participants 

provided with vocational training will 

also receive integrated worker rights 

training in order to ensure that they are 

able to fully benefit from their new 

skills and professions. Similarly, new 

entrepreneurs may become employers 

for the first time and will also receive 

worker rights training to understand 

their responsibilities as employers. 

ILAB is authorized to award and 

administer this program by the 

Department of Labor Appropriations 

Act, 2009, Public Law 111–08, 123 Stat. 

524 (2009). The Cooperative Agreement 

awarded under this initiative will be 

managed by ILAB’s Office of Trade and 

Labor Affairs. The duration of the 

project funded by this solicitation is 

three years. The start date of program 

activities will be negotiated upon award 

of the Cooperative Agreement, but will 

be no later than September 30, 2009. 

The full Solicitation for Grant 

Applications is posted on http:// 

www.Grants.gov under U.S. Department 

of Labor/ILAB. If you need to speak to 

a person concerning these grants, or if 

you have issues regarding access to the 

Grants.gov Web site, you may telephone 

Georgiette Nkpa at 202–693–4584 (not a 

toll-free number). 

Signed at Washington, DC this 17th day of 

June 2009. 

Cassandra Mitchell, 

Grant Officer. 

[FR Doc. E9–14648 Filed 6–22–09; 8:45 am] 

BILLING CODE 4510–28–P